1,241 filings
Page 5 of 63
6-K
SNY
Sanofi
28 Jul 22
Condensed Half-year Consolidated Financial Statements
6:17am
6-K
SNY
Sanofi
20 Jul 22
Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis
12:38pm
6-K
SNY
Sanofi
13 Jul 22
Current report (foreign)
1:40pm
6-K
SNY
Sanofi
8 Jul 22
Sanofi Global Health launches nonprofit Impact® brand for 30 medicines in low-income countries
11:01am
6-K
SNY
Sanofi
30 Jun 22
Current report (foreign)
12:10pm
11-K
SNY
Sanofi
29 Jun 22
Annual report of employee stock purchases
11:48am
11-K
SNY
Sanofi
29 Jun 22
Annual report of employee stock purchases
11:46am
6-K
SNY
Sanofi
28 Jun 22
Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine
3:59pm
6-K
SNY
Sanofi
16 Jun 22
Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron
1:20pm
6-K
SNY
Sanofi
13 Jun 22
FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
2:56pm
6-K
SNY
Sanofi
7 Jun 22
Current report (foreign)
2:51pm
6-K
SNY
Sanofi
31 May 22
Update on Cialis® Rx-to-OTC Switch Actual Use Trial
10:56am
6-K
SNY
Sanofi
25 May 22
FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
1:53pm
SD
SNY
Sanofi
25 May 22
Conflict minerals disclosure
10:10am
S-8
SNY
Sanofi
18 May 22
Registration of securities for employees
3:48pm
6-K
SNY
Sanofi
17 May 22
Current report (foreign)
3:20pm
S-8 POS
SNY
Sanofi
17 May 22
Registration of securities for employees (post-effective amendment)
8:42am
6-K
SNY
Sanofi
16 May 22
IFRS net sales reported
1:45pm
6-K
SNY
Sanofi
9 May 22
Approval of the financial statements for the fiscal year 2021
2:29pm
6-K
SNY
Sanofi
29 Apr 22
Current report (foreign)
12:38pm